Ziopharm Oncology (ZIOP) Reports In-Line Q2 EPS

Ziopharm Oncology (NASDAQ: ZIOP) reported Q2 EPS of ($0.09), in-line with the analyst estimate of ($0.09).

“During the second quarter, we were able to report positive clinical and organizational progress, positioning the Company for additional data readouts in the coming year,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer. “With the completion of enrollment in our phase 2 trial of Controlled IL-12 in combination with Libtayo, and launches of two new trials, we have begun to see encouraging signs of our partners re-emerging despite the COVID-19 outbreak.”

For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.

You May Also Be Interested In

• Sanuwave Q2 2026 revenue tops revised guidance range
• AllianceBernstein AUM rises to $905B at end of June 2026
• Eupraxia Pharmaceuticals adds executives, shifts operations to Vancouver